<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="5417">Glucosamine</z:chebi> (<z:chebi fb="15" ids="17659">UDP</z:chebi>-N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>)-2-epimerase/N-acetylmannosamine kinase (GNE) <z:hpo ids='HP_0003198'>myopathy</z:hpo>, also called distal <z:hpo ids='HP_0003198'>myopathy</z:hpo> with <z:hpo ids='HP_0003805'>rimmed vacuoles</z:hpo> (DMRV) or hereditary inclusion body <z:hpo ids='HP_0003198'>myopathy</z:hpo> (HIBM), is a rare, progressive <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> disorder caused by mutations in the GNE gene </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we examined the relationship between genotype and clinical phenotype in participants with GNE <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Participants with GNE <z:hpo ids='HP_0003198'>myopathy</z:hpo> were asked to complete a questionnaire regarding medical history and current symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 71 participants with genetically confirmed GNE <z:hpo ids='HP_0003198'>myopathy</z:hpo> (27 males and 44 females; mean age, 43.1±13.0 (mean±SD) years) completed the questionnaire </plain></SENT>
<SENT sid="4" pm="."><plain>Initial symptoms (e.g., <z:hpo ids='HP_0003377'>foot drop</z:hpo> and <z:hpo ids='HP_0007340'>lower limb weakness</z:hpo>) appeared at a mean age of 24.8±8.3 years </plain></SENT>
<SENT sid="5" pm="."><plain>Among the 71 participants, 11 (15.5%) had the ability to walk, with a median time to loss of ambulation of 17.0±2.1 years after disease <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Participants with a homozygous mutation (p.V572L) in the N-acetylmannosamine kinase domain (KD/KD participants) had an earlier disease <z:hpo ids='HP_0003674'>onset</z:hpo> compared to compound heterozygous participants with mutations in the <z:chebi fb="0" ids="17659">uridine diphosphate</z:chebi>-N-acetylglucosamine (<z:chebi fb="0" ids="16264">UDP-GlcNAc</z:chebi>) 2-epimerase and N-acetylmannosamine kinase domains (ED/KD participants; 26.3±7.3 vs. 21.2±11.1 years, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>KD/KD participants were more frequently non-ambulatory compared to ED/KD participants at the time of survey (80% vs. 50%) </plain></SENT>
<SENT sid="8" pm="."><plain>Data were verified using medical records available from 17 outpatient participants </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Homozygous KD/KD participants exhibited a more severe phenotype compared to heterozygous ED/KD participants </plain></SENT>
</text></document>